dc.contributor.author | Li, Haojie | |
dc.contributor.author | Stampfer, Meir | |
dc.contributor.author | Mucci, Lorelei | |
dc.contributor.author | Rifai, Nader | |
dc.contributor.author | Qiu, Weiliang | |
dc.contributor.author | Kurth, Tobias | |
dc.contributor.author | Ma, Jing | |
dc.date.accessioned | 2019-09-05T18:09:42Z | |
dc.date.issued | 2010 | |
dc.identifier.citation | Li, H., M. J. Stampfer, L. Mucci, N. Rifai, W. Qiu, T. Kurth, and J. Ma. 2009. “A 25-Year Prospective Study of Plasma Adiponectin and Leptin Concentrations and Prostate Cancer Risk and Survival.” Clinical Chemistry 56 (1): 34–43. https://doi.org/10.1373/clinchem.2009.133272. | |
dc.identifier.issn | 0009-9147 | |
dc.identifier.issn | 1530-8561 | |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292618 | * |
dc.description.abstract | BACKGROUND: Adipocytokines may mediate the association between adiposity and lethal prostate cancer outcomes. Methods: In the Physicians' Health Study, we prospectively examined the association of prediagnostic plasma concentrations of adiponectin and leptin with risk of developing incident prostate cancer (654 cases diagnosed 1982-2000 and 644 age-matched controls) and, among cases, risk of dying from prostate cancer by 2007. Results: Adiponectin concentrations were not associated with risk of overall prostate cancer. However, men with higher adiponectin concentrations had lower risk of developing high-grade or lethal cancer (metastatic or fatal disease). The relative risk (95% CI) comparing the highest quintile to the lowest (Q5 vs Q1) was 0.25 (95% Cl 0.07-0.87; P(trend) = 0.02) for lethal cancer. Among all the cases, higher adiponectin concentrations predicted lower prostate cancer-specific mortality [hazard ratio (HR)(Q5 vs Q1) = 0.39; 95% Cl 0.17-0.85; P(trend) = 0.02], independent of body mass index (BMI), plasma C-peptide (a marker of insulin secretion), leptin, clinical stage, and tumor grade. This inverse association was apparent mainly among men with a BMI >= 25 kg/m(2) (HR(Q5 vs Q1) = 0.10; 95% CI 0.01-0.78; P(trend) = 0.02), but not among men of normal weight (P(trend) = 0.51). Although the correlation of leptin concentrations with BMI (r = 0.58, P < 0.001) was stronger than that of adiponectin (r = -0.17, P < 0.001), leptin was unrelated to prostate cancer risk or mortality. ConclUSIONS: Higher prediagnostic adiponectin (but not leptin) concentrations predispose men to a lower risk of developing high-grade prostate cancer and a lower risk of subsequently dying from the cancer, suggesting a mechanistic link between obesity and poor prostate cancer outcome. | |
dc.language.iso | en_US | |
dc.publisher | American Association for Clinical Chemistry | |
dash.license | LAA | |
dc.title | A 25 Year Prospective Study of Plasma Adiponectin and Leptin Concentrations and Prostate Cancer Risk and Survival | |
dc.type | Journal Article | |
dc.description.version | Accepted Manuscript | |
dc.relation.journal | Clinical Chemistry | |
dash.depositing.author | Stampfer, Meir | |
dc.date.available | 2019-09-05T18:09:42Z | |
dash.workflow.comments | 1Science Serial ID 26248 | |
dc.identifier.doi | 10.1373/clinchem.2009.133272 | |
dash.source.volume | 56;1 | |
dash.source.page | 34 | |
dash.contributor.affiliated | Stampfer, Meir | |